You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Highly-sensitive, rapid and low cost plasmonic assay platform for Lyme disease diagnosis

    SBC: CIENCIA INC            Topic: NIAID

    Project Summary/Abstract Lyme disease (LD) is the most common vector-borne illness in the United States and represents a considerable diagnostic challenge. 1-3 The current benchmark for LD diagnosis is the standard two-tiered test (STTT), although the modified two-tier test (MTTT) is rapidly becoming an acceptable alternative. 6 These assays are highly specific but have poor sensitivity, especiall ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. A novel clot containing system for improved neurothrombectomy outcomes

    SBC: XTRACT MEDICAL INC            Topic: 106

    PROJECT SUMMARY Mechanical thrombectomy (MT) has recently gained impetus as a treatment for acute ischemic stroke (AIS). Although technical progress has been made, the efficacy of the current techniques remains sub-optimal and MT is still associated with significant complications. Current MT techniques, using stent retrievers or aspiration catheters, achieve successful revascularization after the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Segmented negative-sense, single-stranded RNA viruses (sNSVs), which include bunyaviruses, are causative agents of human diseases. Rift Valley Fever Virus (RVFV), a bunyavirus, causes hemorrhagic fever in humans with a case fatality rate of patients developing hemorrhagic fever reaching approximately 50% and has been classified by the NIAID as a Category A Priority Pathogen. RVFV is mosqu ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Broad-Spectrum CyclicAmphiphilic Peptides against Multidrug-Resistant Bacteria

    SBC: AJK BIOPHARMACEUTICAL LLC            Topic: NIAID

    ABSTRACT The emergence of antibacterial resistance to common frontline antibiotics, such as methicillin, vancomycin, cephalosporins, and carbapenem, have created a global public health challenge for millions of patients. It is therefore critical to discover and commercialize new antimicrobial agents that can successfully neutralize multidrug-resistant bacteria (MDRB) with minimal toxicity. The obj ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of protease activity-based detector substrates for diagnosing Candida infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    Project Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City

    SBC: HBI SOLUTIONS INC.            Topic: 100

    ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization

    SBC: FELIX BIOTECHNOLOGY INC            Topic: NIAID

    ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency

    SBC: COURAGE THERAPEUTICS INC            Topic: 102

    The melanocortin peptide therapeutic setmelanotide, (ImcivreeTM), is highly effective in the treatment of the rare obesity syndromes, POMC and leptin receptor deficiency. However, the drug is ineffective for the most common syndromic obesity, melanocortin-4 receptor (MC4R) deficiency (MC4R haploinsufficiency), found at a prevalence greater than 1/1000 individuals. Further, the drug is ineffective ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution

    SBC: Fluid Discovery Inc            Topic: 400

    Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, rema ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government